| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Goldman and Morris), Anatomy and Neurobiology (Dr. Price), Psychology (Dr. Storandt), Pathology (Drs. McKeel and Morris), Psychiatry (Dr. Rubin), the Division of Biostatistics (Dr. Grant), and the Alzheimer’s Disease Research Center, Washington University, St. Louis, MO.
Address correspondence and reprint requests to Dr. John C. Morris, Department of Neurology, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8111 MAP, St. Louis, MO 63110.
OBJECTIVE: To determine whether clinically nondemented elderly individuals with pathologically confirmed preclinical AD are characterized by cognitive decline as measured by psychometric tests before death.
METHODS: Psychometric performance was examined retrospectively in 14 individuals who were nondemented at time of death and grouped in accordance with their neuropathologic findings: 1) Healthy brain (n = 9) was characterized by the absence of senile plaques or by only patchy neocortical deposits of plaques; 2) preclinical AD (n = 5) was characterized by neuritic and diffuse plaques distributed throughout the neocortex. All individuals showed neurofibrillary pathologic change in medial temporal lobe structures. For comparison, we also evaluated 10 individuals who died in the earliest symptomatic stage of dementia of the Alzheimer type (DAT). All individuals had been assessed by clinical and psychometric measures during life. The psychometric measures yielded a standardized factor score that represented global cognitive performance.
RESULTS: At the last assessment before death, individuals with very mild DAT were impaired on the factor score and on individual psychometric measures with respect to the nondemented individuals. Those nondemented individuals with preclinical AD did not differ in performance from those with healthy brains. For individuals with at least three psychometric assessments during life, there was no decline in performance for either those with healthy brains (n = 5) or preclinical AD (n = 3), although decline was evident for very mild DAT individuals (n = 5).
CONCLUSIONS: Pathologically confirmed preclinical AD is not associated with cognitive impairment or decline, even on measures shown to be sensitive to very mild DAT.
This article has been cited by other articles:
|
|
 |
|
  E. C. Mormino, J. T. Kluth, C. M. Madison, G. D. Rabinovici, S. L. Baker, B. L. Miller, R. A. Koeppe, C. A. Mathis, M. W. Weiner, W. J. Jagust, et al. Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects Brain, May 1, 2009; 132(5): 1310 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Erten-Lyons, R. L. Woltjer, H. Dodge, R. Nixon, R. Vorobik, J. F. Calvert, M. Leahy, T. Montine, and J. Kaye Factors associated with resistance to dementia despite high Alzheimer disease pathology Neurology, January 27, 2009; 72(4): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Aizenstein, R. D. Nebes, J. A. Saxton, J. C. Price, C. A. Mathis, N. D. Tsopelas, S. K. Ziolko, J. A. James, B. E. Snitz, P. R. Houck, et al. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly Arch Neurol, November 1, 2008; 65(11): 1509 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Garibotto, B. Borroni, E. Kalbe, K. Herholz, E. Salmon, V. Holtoff, S. Sorbi, S. F. Cappa, A. Padovani, F. Fazio, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence Neurology, October 21, 2008; 71(17): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Fotenos, M. A. Mintun, A. Z. Snyder, J. C. Morris, and R. L. Buckner Brain Volume Decline in Aging: Evidence for a Relation Between Socioeconomic Status, Preclinical Alzheimer Disease, and Reserve Arch Neurol, January 1, 2008; 65(1): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Blacker, H. Lee, A. Muzikansky, E. C. Martin, R. Tanzi, J. J. McArdle, M. Moss, and M. Albert Neuropsychological Measures in Normal Individuals That Predict Subsequent Cognitive Decline Arch Neurol, June 1, 2007; 64(6): 862 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Scheff, D. A. Price, F. A. Schmitt, S. T. DeKosky, and E. J. Mufson Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment Neurology, May 1, 2007; 68(18): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kudo, N. Okamura, S. Furumoto, M. Tashiro, K. Furukawa, M. Maruyama, M. Itoh, R. Iwata, K. Yanai, and H. Arai 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients J. Nucl. Med., April 1, 2007; 48(4): 553 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Klunk, C. A. Mathis, J. C. Price, B. J. Lopresti, and S. T. DeKosky Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, November 1, 2006; 129(Pt 11): 2805 - 2807. [Full Text] [PDF]
|
|
|
|
|
|
I. Prohovnik, D. P. Perl, K. L. Davis, L. Libow, G. Lesser, and V. Haroutunian Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease Neurology, January 10, 2006; 66(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Markesbery, F. A. Schmitt, R. J. Kryscio, D. G. Davis, C. D. Smith, and D. R. Wekstein Neuropathologic Substrate of Mild Cognitive Impairment Arch Neurol, January 1, 2006; 63(1): 38 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Hartman, Y. Izumi, K. R. Bales, S. M. Paul, D. F. Wozniak, and D. M. Holtzman Treatment with an Amyloid-{beta} Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease J. Neurosci., June 29, 2005; 25(26): 6213 - 6220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Galvin, K. K. Powlishta, K. Wilkins, D. W. McKeel Jr, C. Xiong, E. Grant, M. Storandt, and J. C. Morris Predictors of Preclinical Alzheimer Disease and Dementia: A Clinicopathologic Study Arch Neurol, May 1, 2005; 62(5): 758 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Howieson, R. Camicioli, J. Quinn, L. C. Silbert, B. Care, M. M. Moore, A. Dame, G. Sexton, and J. A. Kaye Natural history of cognitive decline in the old old Neurology, May 13, 2003; 60(9): 1489 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Scarmeas, E. Zarahn, K. E. Anderson, C. G. Habeck, J. Hilton, J. Flynn, K. S. Marder, K. L. Bell, H. A. Sackeim, R. L. Van Heertum, et al. Association of Life Activities With Cerebral Blood Flow in Alzheimer Disease: Implications for the Cognitive Reserve Hypothesis Arch Neurol, March 1, 2003; 60(3): 359 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Pompl, S. Yemul, Z. Xiang, L. Ho, V. Haroutunian, D. Purohit, R. Mohs, and G. M. Pasinetti Caspase Gene Expression in the Brain as a Function of the Clinical Progression of Alzheimer Disease Arch Neurol, March 1, 2003; 60(3): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Morris, J. Csernansky, J. L. Price, R. Killiany, B. T. Hyman, and M. S. Albert MRI measures of entorhinal cortex versus hippocampus in preclinical AD Neurology, November 12, 2002; 59(9): 1474 - 1475. [Full Text] [PDF]
|
|
|
|
|
|
A. Delacourte, N. Sergeant, D. Champain, A. Wattez, C.-A. Maurage, F. Lebert, F. Pasquier, and J.-P. David Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease Neurology, August 13, 2002; 59(3): 398 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bennett, R. S. Wilson, J. A. Schneider, D. A. Evans, L. A. Beckett, N. T. Aggarwal, L. L. Barnes, J. H. Fox, and J. Bach Natural history of mild cognitive impairment in older persons Neurology, July 23, 2002; 59(2): 198 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Small, L. Fratiglioni, and L. Backman Canaries in a Coal Mine: Cognitive Markers of Preclinical Alzheimer Disease Arch Gen Psychiatry, September 1, 2001; 58(9): 859 - 860. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Price, A. I. Ko, M. J. Wade, S. K. Tsou, D. W. McKeel, and J. C. Morris Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease Arch Neurol, September 1, 2001; 58(9): 1395 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Defining the Onset of Alzheimer's Disease Journal Watch Psychiatry, March 22, 2001; 2001(322): 11 - 11. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
